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a b s t r a c t
A 59-year old woman who attended the emergency department because of a bilateral
peripheral facial nerve palsy (FNP). Bilateral FNP is uncommon, an idiopathic cause is
unlikely and consequently a comprehensive study is indicated. An IgM monoclonal gam-
mopathy was detected on serum protein electrophoresis of our patient. Bone marrow
biopsy showed the presence of lymphoplasmocytoid cells. On the basis of these findings
the diagnosis of Waldenström's macroglobulinemia (WM) was made. Secondary cranial
nerve palsies are rarely seen in this condition. This report describes a case of bilateral FNP
as initial presentation of a Waldenström's macroglobulinemia and discuss treatment.
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Idiopathic facial nerve palsy (FNP), or Bell's palsy, is the
most prevalent acute disorder affecting the seventh cranial
nerve with an incidence of 20–30 patients per 100 000.
Conversely, bilateral FNP is rare, representing less than 2%
of all the facial palsies and affecting five patients per
100 000. Most of these patients have serious underlying
medical conditions and need to be evaluated carefully [1].
Waldenström's macroglobulinemia (WM) is a rare low-
grade B-cell lymphoma characterized by involvement of the
reticuloendothelial system by lymphoplasmacytoid cells* Corresponding author at: Paseo Castellana 261, 28046 Madrid, Spain.
E-mail address: msorgaz@gmail.com (M. Sánchez-Orgaz).
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Urban & Partner Sp. z o.o. All rights reserved.which secrete monoclonal IgM. Uncontrolled production of
this immunoglobulin increases serum viscosity and causes
tumor cell infiltration of the tissues. Up to 47% of patients
with WM develop symptomatic peripheral neuropathy but
cranial nerve palsies are rare in this condition [2]. We
describe a case of WM presenting as bilateral FNP.
Case report
A 59-year old lady attended the emergency room presenting
symptoms of left facial numbness and weakness, inability
to close her left eye and asymmetry of the mouth. The Tel.: +34 653540699.
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with prednisone 30 mg three times a day was prescribed.
Two days later, she returned because of worsening symp-
toms; the facial weakness became bilateral and she had
secondary dysarthria. Examination revealed bilateral lower
motor neuron FNP (Fig. 1). The rest of the neurological
examination was unremarkable. The patient had no medical
history of interest, except for a recent trip to Kenya and
Tanzania, where she referred a mosquito-bite. She had
taken antimalarial prophylaxis with proguanil correctly.
The complete blood count, biochemical analysis, chest X-
ray and head computer tomography were normal. The
patient was hospitalized under the care of the neurology
department with the suspect of bilateral Guillain-Barré syn-
drome. She started treatment with intravenous corticoster-
oids and oral doxycycline until Lyme disease was ruled out.
Lumbar puncture revealed proteinorrachia (463 mg/L) and
an increase of IgM index (0.23), adenosine deaminase (5 m/L)
and neuron specific enolase (35.1 ng/ml). Serological tests
for various agents including Borrelia burgdorferi (Lyme dis-
ease), syphilis and Epstein-Barr virus were negative. Like-
wise, the culture of cerebrospinal fluid and tumor cytology
were both negative.
Head magnetic resonance imaging (MRI) showed bilateral
asymmetrical enhancement of the facial nerves, with left-
sided predominance.
Nerve conduction studies showed no alteration of per-
ipheral nerve conduits, consequently Guillain-Barré was
ruled out. At that time, facial electroneurography (ENG) was
inconclusive, while a month later, it revealed a mixed
lesion: axonal and demyelinating with more severe affection
of the left side.
A monoclonal IgM spike was detected in serum protein
electrophoresis with an increased level of b2-microglobulin.
Bone marrow biopsy revealed nodular intertrabecular infil-
tration by a low grade B non-Hodgkin lymphoma. The
immunophenotype profile of the lymphoplasmocytoid cells
was CD20+, CD3, CD5, CD23, bcl-6- and CD10 consis-
tent with the diagnosis of WM. The patient received six
cycles of ambulant systemic chemotherapy and immu-
notherapy based on DRC-scheme: dexamethasone, rituxi-
mab (375 mg/m3) and cyclophosphamide, spaced over eight
weeks. Treatment with artificial tears and ointment and eye
patching during night was prescribed because of the high
risk of exposure keratopathy.Fig. 1 – The patient ten days after facial palsy. InThree months later, the demyelinating component recov-
ered on ENG and reinnervation of both facial nerves began.
Improvement correlated with a dramatic decrease in IgM
levels, antibody titles and circulating B cells. Lagophthalmos
(inability to close the eyes) improved and, ophthalmological
examination showed only mild punctate superficial kerato-
pathy in the left eye.
Nine months after diagnosis, IgM levels have declined
more. The patient presents a mild facial asymmetry with
absence of lagophthalmos in both eyes (Fig. 2), the smile was
restored and the nasolabial fold has been corrected. The
electromyogram (EMG) shows an improvement of both facial
nerve reinnervation and functional recovery especially of the
orbicularis oculi muscle and the lips. As well, a moderate
increment of the motor activity could be detected.
Aberrant reinnervation was demonstrated by EMG, clini-
cally expressed by sinkynesis, and a pathological spread of
the reflex response of both facial nerves to unusual terri-
tories, especially on the left side.
The patients will continue treatment with rituximab-
cycles every eight weeks until two year completion.
Discussion
Bilateral FNP is an infrequent disease and a serious under-
lying medical condition should be suspected. Possible causes
include infectious, autoimmune and metabolic diseases,
tumors, toxic and congenital disorders. There are several viral
and bacterial agents which can produce bilateral or recurrent
FNP. Lyme disease, caused by spirochete Borrelia burgdorferi, is
the most common infectious etiology, followed by Epstein-
Barr virus. Guillain-Barré Syndrome (inflammatory post-infec-
tious polyradiculoneuritis) is another important cause of
bilateral FNP to be ruled out, because up to 50% of fatal cases
can occur. As well, intrapontine and prepontine tumors
should be excluded. There is one reported case of bilateral
FNP and acute myeloid leukemia [3].
WM is considered an indolent form of B-cell non-Hodgkin
lymphoma, also known as lymphoplasmocytic lymphoma by
the World Health Organization (WHO) classification.
Infiltration by lymphoplasmacytic cells, predominantly of
the bone marrow together with an IgM monoclonal gammo-
pathy, is considered a diagnostic finding [4]. WM accounts
for 1–2% of all hematologic malignancies and in terms ofability to close both eyes, specially the left
Fig. 2 – The patient nine months after facial palsy. Recovery of lagophthalmos and occlusion of both eyes
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monoclonal gammopathy of unknown significance (MGUS)
and multiple myeloma. The disease most commonly affects
men above 60 years of age. Typically manifestations are
diffuse lymphadenopathies, cytopenias and a markedly ele-
vated erythrocyte sedimentation rate. Clinical symptoms are
due to the monoclonal IgM protein, tissue infiltration by the
lymphoplasmocytic cells, or both [5]. Hyperviscosity retino-
pathy is the most common ocular abnormality reported in
WM [6]. Peripheral neuropathy (PN) is a frequent complica-
tion of IgM monoclonal gammopathy, occurring in 15–30%
of patients with either MGUS, most commonly, or WM.
Of the whole spectrum of peripheral neuropathies, the
typical pattern consists in a chronic progressive symmetric
and predominantly distal polyneuropathy, but also other
symmetric polyneuropathies, cranial nerve palsies, mono-
neuropathies and mononeuritis multiplex. Isolated cranial
neuropathies are rare in WM [2]. About 25% of patients with
WM suffer from central nervous system (CNS) symptoms
secondary to increased blood viscosity (Bing-Neel syndrome)
leading to anoxic damage and hemorrhages of the brain
tissues. In the context of CNS involvement cranial nerve
palsies are more common. We found a case report of
bilateral sixth nerve palsy in a patient with Bing-Neel
syndrome [7]. To our knowledge there is no case report
about facial diplegia secondary to this entity. Moreover,
during literature review we have only found one report of
isolated trochlear nerve palsy [8], another of unilateral facial
nerve palsy [9], in the absence of other nervous system
manifestations.
IgM has been found to have anti-nerve antibody activity.
The most frequently reported antigen recognized by this
monoclonal IgM is myelin-associated glycoprotein (MAG).
The mechanism by which anti-MAG enters the nerve and
causes demyelination and neural damage is unclear. Other
neural antigens have also been associated with polyneuro-
pathies including several anti-gangliosides (antiGM1), sulfa-
tide and tri-sulfated heparin disaccharide [10]. Non-
antibody-mediated mechanisms have also been implicatedin patients without antineural reactivity of IgM paraprotein:
cryoglobulinemia, direct lymphoplasmacytic infiltration of
the nerves, and vasculitis.
Anti-gangliosides and anti-sulfatides were not detected
in our patient but anti-MAG were positive, so we think, that
in our case the mechanism involved was autoimmune. In
addition, improvement of the FNP after rituximab and
corticosteroids supports the antibody mediated response
rather than tumoral nerve infiltration.
A watch and wait strategy is recommended in asympto-
matic patients with WM (almost a third of them), with
periodic examinations every six months.
Administration of intravenous immunoglobulin is one of
the most commonly used first-line therapies for anti-MAG
antibody associated polyneuropathy in MGUS. The treat-
ment seems to provide short-term benefit, although data
from prospective long-term studies are unavailable [11]. It
seems reasonable to provide this treatment to patients
with WM and IgM-related neuropathy, in conjunction with
tumor-directed treatments. As per the previous recommen-
dations of IWWM-4, dexamethasone, rituximab, and cyclo-
phosphamide (DRC) remains the primary choice. Rituximab
is a chimeric antibody that targets the B-cell antigen CD20
(375 mg/m3 weekly for 4 weeks). Further doses or main-
tenance schedules can be considered [12]. A consensus
panel has recently updated treatment for WM [13]. The
treatment of IgM-related neuropathy may initially involve
a course of plasmapheresis, especially in symptomatic
patients with an aggressive course and circulating antibo-
dies against peripheral nerve glycoproteins or lipids
expected to receive rituximab. Systemic chemotherapy
with rituximab improve sensory functions in several stu-
dies. Single-agent rituximab can be considered as the first
intervention in patients with mild, slowly progressive
neuropathy. In patients with severe or refractory disease,
the combination of fludaravine (a nucleoside analog) and
rituximab may be considered. Bendamustine/rituximab
may achieve paraprotein reductions but there is limited
experience in IgM-related neuropathy.
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immunotherapy based on DRC-scheme with good response.
Fludaravine-rituximab is effective but toxic, and DRC is safe.
The identification of the somatic mutations MyD88 and
CXCR4 offers the opportunity for a more targeted approach
[14, 15].
Novel agents such as abrutinib, Ixazomib, oprozomib and
obinutuzumab (GA-101) a new monoclonal anti-CD20 anti-
body recently approved, are being studied. A prospective,
open-label, single stage, phase 2 study concludes that,
carfilzomib (second-generation proteasome inhibitor), ritux-
imab and dexamethasone (CaRD) offers a neuropathy-spar-
ing approach for treating WM.
Autologous stem cell transplantation may be considered
in young patients with chemosensitive disease and in newly
diagnosed patients with very high-risk features.
In conclusion, although an idiopathic etiology is possible
in bilateral FNP, efforts should be undertaken to identify
a specific cause in each patient because some of the
diagnostic possibilities are life-threatening and potentially
fatal.
Update results from the phase 2 DRC study indicate that
this is an effective strategy for many patients with WM and
paraprotein-related neuropathy. For patients with short-
lasting remission, progressive disease or resistance to
a first-line therapy, second-line treatment with agents of
different class, alone or in combination is indicated. Large,
well designed randomized trials are required to establish
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